RT Journal Article
SR Electronic
T1 Studying the pathophysiology of coronavirus disease 2019 – a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20092833
DO 10.1101/2020.05.06.20092833
A1 Kurth, Florian
A1 Roennefarth, Maria
A1 Thibeault, Charlotte
A1 Corman, Victor M.
A1 Müller-Redetzky, Holger
A1 Mittermaier, Mirja
A1 Ruwwe-Glösenkamp, Christoph
A1 Krannich, Alexander
A1 Schmidt, Sein
A1 Kretzler, Lucie
A1 Dang-Heine, Chantip
A1 Rose, Matthias
A1 Hummel, Michael
A1 Hocke, Andreas
A1 Hübner, Ralf H.
A1 Mall, Marcus A.
A1 Röhmel, Jobst
A1 Landmesser, Ulf
A1 Pieske, Burkert
A1 Knauss, Samuel
A1 Endres, Matthias
A1 Spranger, Joachim
A1 Mockenhaupt, Frank P.
A1 Tacke, Frank
A1 Treskatsch, Sascha
A1 Angermair, Stefan
A1 Siegmund, Britta
A1 Spies, Claudia
A1 Weber-Carstens, Steffen
A1 Eckardt, Kai-Uwe
A1 Uhrig, Alexander
A1 Zoller, Thomas
A1 Drosten, Christian
A1 Suttorp, Norbert
A1 Witzenrath, Martin
A1 Hippenstiel, Stefan
A1 Kalle, Christof von
A1 Sander, Leif Erik
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.06.20092833.abstract
AB Purpose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a global health emergency. Pa-COVID-19 aims to provide comprehensive data on clinical course, pathophysiology, immunology and outcome of COVID-19, in order to identify prognostic biomarkers, clinical scores, and therapeutic targets for improved clinical management and preventive interventions.Methods Pa-COVID-19 is a prospective observational cohort study of patients with confirmed SARS-CoV-2 infection treated at Charité - Universitätsmedizin Berlin. We collect data on epidemiology, demography, medical history, symptoms, clinical course, pathogen testing and treatment. Systematic, serial blood sampling will allow deep molecular and immunological phenotyping, transcriptomic profiling, and comprehensive biobanking. Longitudinal data and sample collection during hospitalization will be supplemented by long-term follow-up.Results Outcome measures include the WHO clinical ordinal scale on day 15 and clinical, functional and health-related quality of life assessments at discharge and during follow-up. We developed a scalable dataset to (i) suit national standards of care (ii) facilitate comprehensive data collection in medical care facilities with varying resources and (iii) allow for rapid implementation of interventional trials based on the standardized study design and data collection. We propose this scalable protocol as blueprint for harmonized data collection and deep phenotyping in COVID-19 in Germany.Conclusion We established a basic platform for harmonized, scalable data collection, pathophysiological analysis, and deep phenotyping of COVID-19, which enables rapid generation of evidence for improved medical care and identification of candidate therapeutic and preventive strategies. The electronic database accredited for interventional trials allows fast trial implementation for candidate therapeutic agents.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is currently being registered in the German clinical trials register and the WHO International Clinical Trials Registry Platform (ID: DRKS00021688).Funding Statementnot applicableAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe study protocol shall serve as a blueprint for studies conducted on patients infected with SARS-CoV-2 in Germany. https://studycenter.charite.de/covid_19/